We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Promising Immunotherapy Could Potentially Extend Healthy Human Lifespan

A scientist in a lab.
Credit: iStock.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

A Brock-led international research team has discovered a groundbreaking immunotherapy method that could potentially add years to healthy aging.

The research, published in the journal EMBO Molecular Medicine, introduces an innovative method to address health issues arising from poor lifestyle choices, which can cause damage to biomolecules and contribute to the development of diseases later in life.

Professor of Health Sciences Newman Sze and his team developed an approach that involves directing the immune system to clear out accumulated proteins damaged by inactive lifestyles, unhealthy diets, various stresses and genetic factors, root causes of aging and age-related diseases.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

“Age-related chronic diseases are a major health-care burden,” says Sze, the Canada Research Chair in Mechanisms of Health and Disease. “We therefore developed a first-of-its-kind monoclonal antibody drug that harnesses the immune system to target and remove these abnormal proteins, providing an effective treatment for age-related health problems.”

As time passes, environmental stresses and physiological conditions cause biomolecular damages in tissues. One of these changes, called isoDGR, triggers chronic inflammation in the body and leads to tissue degeneration.

Uncontrolled chronic inflammation, in turn, can lead to conditions such as cardiovascular disease, cancer, Type 2 diabetes, arthritis and Alzheimer’s disease.

While the accumulation of isoDGR has been identified as a ‘molecular clock’ of aging, the new research paper says potential benefits of targeting these structures with specific immunotherapies remain largely unknown.

Sze and his team created monoclonal antibodies called isoDGR-mAb. These lab-engineered proteins are designed to boost the immune system’s ability to attack unhealthy cells or abnormal molecules. Such immunotherapies are already being used to treat various cancers, autoimmune disorders and infectious diseases.

Using animal models, the team found that these lab-engineered molecules stimulated the immune system to clear out the proteins in tissues that had been damaged by isoDGR. Treatment with isoDGR-mAb not only doubled lifespan but also preserved behaviour and co-ordination functions and reduced pro-inflammatory cytokine levels in the circulation and body tissues.

Sze says the team’s findings could lead to the development of immunotherapy-based interventions to extend the healthy lifespan of humans.

“The existing treatments for age-related diseases primarily address symptoms,” says Sze. “Our pioneering mAb, uniquely focused on targeting the root causes of chronic diseases, is anticipated to substantially extend human health span.”

As Canada Research Chair, Sze studies diseases that occur as people age, specifically diseases related to the brain and the blood vessels becoming damaged. His lab has developed new research methods that investigate how body tissues deteriorate over time, and created new drugs to guide the immune system to eliminate abnormal biomolecules.

Reference: Kalailingam P, Mohd‐Kahliab K, Ngan SC, et al. Immunotherapy targeting isoDGR ‐protein damage extends lifespan in a mouse model of protein deamidation. EMBO Mol Med. 2023:e18526. doi: 10.15252/emmm.202318526

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.